Elucidating the functionality of kinesins: An overview of small molecule inhibitors

Seminars in Cell and Developmental Biology

Volumn 22, Issue 9, 2011, Pages 935-945

  Good, James A D ^a   Skoufias, Dimitrios A ^b   Kozielski, Frank ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Chemical biology; Chemical genetics; Drug targets; Mitotic kinesins

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BTB 1; GSK 923295; ISPINESIB; KINESIN; KINESIN 1; KINESIN 12; KINESIN 13; KINESIN 14; KINESIN 5; KINESIN 6; KINESIN 7; KINESIN 8; MONASTROL; NATURAL PRODUCT; PAPROTRAIN; PROTEIN INHIBITOR; SB 743921; SULFOQUINOVOSYLACYLGLYCEROL; SYNTELIN; THIAZOLE DERIVATIVE; UA 62784; UNCLASSIFIED DRUG;

CELL TRANSPORT; CHEMICAL GENETICS; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; MITOSIS; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW;

EID: 82755185858     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2011.09.023     Document Type: Review

References (112)

1. Mitchison T.J. Towards a pharmacological genetics. Chem Biol 1994, 1:3-6.
2. Mayer T.U. Chemical genetics: tailoring tools for cell biology. Trends Cell Biol 2003, 13:270-277.
3. Hathaway N.A., King R.W. Dissecting cell biology with chemical scalpels. Curr Opin Cell Biol 2005, 17:12-19.
4. Lampson M.A., Kapoor T.M. Unraveling cell division mechanisms with small-molecule inhibitors. Nat Chem Biol 2006, 2:19-27.
5. Hirokawa N., Noda Y., Tanaka Y., Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 2009, 10:682-696.
6. Lawrence C.J., Dawe R.K., Christie K.R., Cleveland D.W., Dawson S.C., Endow S.A., et al. A standardized kinesin nomenclature. J Cell Biol 2004, 167:19-22.
7. Hunter A.W., Caplow M., Coy D.L., Hancock W.O., Diez S., Wordeman L., et al. The kinesin-related protein MCAK is a microtubule depolymerase that forms an ATP-hydrolyzing complex at microtubule ends. Mol Cell 2003, 11:445-457.
8. Hirokawa N., Takemura R. Kinesin superfamily proteins 2003, Wiley-VCH, Weinheim.
9. Bergnes G., Brejc K., Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 2005, 5:127-145.
10. Sarli V., Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008, 14:7583-7587.
11. Huszar D., Theoclitou M.E., Skolnik J., Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009, 28:197-208.
12. Vale R.D., Reese T.S., Sheetz M.P. Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 1985, 42:39-50.
13. Brady S.T. A novel brain ATPase with properties expected for the fast axonal transport motor. Nature 1985, 317:73-75.
14. Xia C-h, Rahman A., Yang Z., Goldstein L.S.B. Chromosomal localization reveals three kinesin heavy chain genes in mouse. Genomics 1998, 52:209-213.
15. Gindhart J.G. Towards an understanding of kinesin-1 dependent transport pathways through the study of protein-protein interactions. Brief Funct Genomic Proteomic 2006, 5:74-86.
16. Sakowicz R., Berdelis M.S., Ray K., Blackburn C.L., Hopmann C., Faulkner D.J., et al. A marine natural product inhibitor of kinesin motors. Science 1998, 280:292-295.
17. Brier S., Carletti E., DeBonis S., Hewat E., Lemaire D., Kozielski F. The marine natural product adociasulfate-2 as a tool to identify the MT-binding region of kinesins. Biochemistry 2006, 45:15644-15653.
18. Reddie K.G., Roberts D.R., Dore T.M. Inhibition of kinesin motor proteins by adociasulfate-2. J Med Chem 2006, 49:4857-4860.
19. Blackburn C.L., Hopmann C., Sakowicz R., Berdelis M.S., Goldstein L.S., Faulkner D.J. Adociasulfates 1-6, inhibitors of kinesin motor proteins from the sponge Haliclona (aka Adocia) sp. J Org Chem 1999, 64:5565-5570.
20. Kalaitzis J.A., de Almeida Leone P., Harris L., Butler M.S., Ngo A., Hooper J.N., et al. Adociasulfates 1, 7, and 8: new bioactive hexaprenoid hydroquinones from the marine sponge Adocia sp. J Org Chem 1999, 64:5571-5574.
21. Kalaitzis J.A., Quinn R.J. Adociasulfate-9, a new hexaprenoid hydroquinone from the Great Barrier Reef sponge Adocia aculeata. J Nat Prod 1999, 62:1682-1684.
22. Blackburn C.L., Faulkner D.J. Adociasulfate 10, a new merohexaprenoid sulfate from the sponge Haliclona (aka Adocia) sp. Tetrahedron 2000, 56:8429-8432.
23. West L.M., Faulkner D.J. Hexaprenoid hydroquinones from the sponge Haliclona (aka Adocia) sp. J Nat Prod 2006, 69:1001-1004.
24. Bogenstaetter M., Limberg A., Overman L.E., Tomasi A.L. Enantioselective total synthesis of the kinesin motor protein inhibitor adociasulfate 1. J Am Chem Soc 1999, 121:12206-12207.
25. Hopkins S.C., Vale R.D., Kuntz I.D. Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000, 39:2805-2814.
26. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 2002, 45:1712-1722.
27. Learman S.S., Kim C.D., Stevens N.S., Kim S., Wojcik E.J., Walker R.A. NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site. Biochemistry 2009, 48:1754-1762.
28. Prudent R., Moucadel V., Laudet B., Barette C., Lafanechère L., Hasenknopf B., et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008, 15:683-692.
29. Oguchi Y., Uchimura S., Ohki T., Mikhailenko S.V., Ishiwata S. The bidirectional depolymerizer MCAK generates force by disassembling both microtubule ends. Nat Cell Biol 2011, 13:846-852.
30. Mazumdar M., Misteli T. Chromokinesins: multitalented players in mitosis. Trends Cell Biol 2005, 15:349-355.
31. Rieder C.L., Salmon E.D. Motile kinetochores and polar ejection forces dictate chromosome position on the vertebrate mitotic spindle. J Cell Biol 1994, 124:223-233.
32. Yen T.J., Li G., Schaar B.T., Szilak I., Cleveland D.W. CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 1992, 359:536-539.
33. Du Y., English C.A., Ohi R. The kinesin-8 Kif18A dampens microtubule plus-end dynamics. Curr Biol 2010, 20:374-380.
34. Ems-McClung S.C., Walczak C.E. Kinesin-13s in mitosis: Key players in the spatial and temporal organization of spindle microtubules. Semin Cell Dev Biol 2010, 21:276-282.
35. Bakhoum S.F., Thompson S.L., Manning A.L., Compton D.A. Genome stability is ensured by temporal control of kinetochore-microtubule dynamics. Nat Cell Biol 2009, 11:27-35.
36. Kline-Smith S.L., Khodjakov A., Hergert P., Walczak C.E. Depletion of centromeric MCAK leads to chromosome congression and segregation defects due to improper kinetochore attachments. Mol Biol Cell 2004, 15:1146-1159.
37. Gruneberg U., Neef R., Honda R., Nigg E.A., Barr F.A. Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J Cell Biol 2004, 166:167-172.
38. Zhu C., Jiang W. Cell cycle-dependent translocation of PRC1 on the spindle by Kif4 is essential for midzone formation and cytokinesis. Proc Natl Acad Sci USA 2005, 102:343-348.
39. Mishima M., Pavicic V., Gruneberg U., Nigg E.A., Glotzer M. Cell cycle regulation of central spindle assembly. Nature 2004, 430:908-913.
40. Abaza A., Soleilhac J.M., Westendorf J., Piel M., Crevel I., Roux A., et al. M phase phosphoprotein 1 is a human plus-end-directed kinesin-related protein required for cytokinesis. J Biol Chem 2003, 278:27844-27852.
41. Chua P.R., Roof D.M., Lee Y., Sakowicz R., Clarke D., Pierce D., et al. Effective killing of the human pathogen Candida albicans by a specific inhibitor of non-essential mitotic kinesin Kip1p. Mol Microbiol 2007, 65:347-362.
42. Ohsugi M., Adachi K., Horai R., Kakuta S., Sudo K., Kotaki H., et al. Kid-mediated chromosome compaction ensures proper nuclear envelope formation. Cell 2008, 132:771-782.
43. Ferenz N.P., Gable A., Wadsworth P. Mitotic functions of kinesin-5. Semin Cell Dev Biol 2010, 21:255-259.
44. Enos A.P., Morris N.R. Mutation of a gene that encodes a kinesin-like protein blocks nuclear division in A. nidulans. Cell 1990, 60:1019-1027.
45. Knight S.D., Parrish C.A. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP. Curr Top Med Chem 2008, 8:888-904.
46. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286:971-974.
47. Yan Y., Sardana V., Xu B., Homnick C., Halczenko W., Buser C.A., et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 2004, 335:547-554.
48. Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells?. J Cell Sci 2009, 122:2579-2585.
49. Knox J.J., Gill S., Synold T.W., Biagi J.J., Major P., Feld R., et al. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs 2008, 26:265-272.
50. O'Connor O. A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. Ann Oncol 2008, 19:162-163.
51. Lee C.W., Belanger K., Rao S.C., Petrella T.M., Tozer R.G., Wood L., et al. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008, 26:249-255.
52. DeBonis S., Simorre J.P., Crevel I., Lebeau L., Skoufias D.A., Blangy A., et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003, 42:338-349.
53. Maliga Z., Mitchison T.J. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC Cell Biol 2006, 6:2.
54. Parrish C.A., Adams N.D., Auger K.R., Burgess J.L., Carson J.D., Chaudhari A.M., et al. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 2007, 50:4939-4952.
55. Luo L., Parrish C.A., Nevins N., McNulty D.E., Chaudhari A.M., Carson J.D., et al. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 2007, 3:722-726.
56. Rickert K.W., Schaber M., Torrent M., Neilson L.A., Tasber E.S., Garbaccio R., et al. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 2008, 469:220-231.
57. Teng J., Rai T., Tanaka Y., Takei Y., Nakata T., Hirasawa M., et al. The KIF3 motor transports N-cadherin and organizes the developing neuroepithelium. Nat Cell Biol 2005, 7:474-482.
58. Tomasi A, Morgan BP, Morgans DJ, McDonald A, Roof D, Maxon M, inventors; Cytokinetics, Inc., USA, assignee. Compounds, compositions, and methods using substituted indoles for treating fungal infections by modulating kinesin Kip1. World patent WO 2004098494. 2004 Apr 29.
59. Morgans DJ, Morgan BP, Tomasi A, Wang J, inventors; Cytokinetics, Inc., USA, assignee. A preparation of heterocyclic compounds, useful for the treatment of fungal infections. World patent WO 2005005382. 2005 Jan 20.
60. Lai F., Fernald A.A., Zhao N., Le Beau M.M. cDNA cloning, expression pattern, genomic structure and chromosomal location of RAB6KIFL, a human kinesin-like gene. Gene 2000, 248:117-125.
61. Fontijn R.D., Goud B., Echard A., Jollivet F., van Marle J., Pannekoek H., et al. The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol 2001, 21:2944-2955.
62. Hill E., Clarke M., Barr F.A. The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. EMBO J 2000, 19:5711-5719.
63. Neef R., Klein U.R., Kopajtich R., Barr F.A. Cooperation between mitotic kinesins controls the late stages of cytokinesis. Curr Biol 2006, 16:301-307.
64. Neef R., Preisinger C., Sutcliffe J., Kopajtich R., Nigg E.A., Mayer T.U., et al. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J Cell Biol 2003, 162:863-875.
65. Tcherniuk S., Skoufias D.A., Labriere C., Rath O., Gueritte F., Guillou C., et al. Relocation of Aurora B and Survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed 2010, 49:8228-8231.
66. Labriere C, Gueritte F, Kozielski F, Tcherniuk S, Skoufias DA, Thal C, et al., inventors; Centre National de la Recherche Scientifique, France, assignee. Use of derivates of indoles for the treatment of cancer. World patent WO 2010150211. 2010 Dec 29.
67. Kamimoto T., Zama T., Aoki R., Muro Y., Hagiwara M. Identification of a novel kinesin-related protein, KRMP1, as a target for mitotic peptidyl-prolyl isomerase Pin1. J Biol Chem 2001, 276:37520-37528.
68. Kanehira M., Katagiri T., Shimo A., Takata R., Shuin T., Miki T., et al. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res 2007, 67:3276-3285.
69. Obara W., Tsunoda T., Yoshida K., Kanehira M., Takata R., Katagiri T., et al. Phase I/II study of novel HLA-A24 restricted DEPDC1 and MPHOSPH1 peptide vaccine for bladder cancer. J Clin Oncol 2010, 28:e13122. (Meeting abstracts).
70. Nigg EA, Mayer TU, Huemmer S, Barr F, Nbormann J, inventors; Max-Planck-Gesellschaft Zur Foerderung der Wissenschaften e.v., Germany, assignee. 2-Phenylquinoxalines as inhibitors of MPP1 for treatment of proliferative diseases. World patent WO 2006-EP459. 2006 Aug 3.
71. Wood K.W., Sakowicz R., Goldstein L.S.B., Cleveland D.W. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 1997, 91:357-366.
72. Putkey F.R., Cramer T., Morphew M.K., Silk A.D., Johnson R.S., McIntosh J.R., et al. Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 2002, 3:351-365.
73. Chan G.K., Jablonski S.A., Sudakin V., Hittle J.C., Yen T.J. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 1999, 146:941-954.
74. Yao X., Abrieu A., Zheng Y., Sullivan K.F., Cleveland D.W. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2000, 2:484-491.
75. Abrieu A., Kahana J.A., Wood K.W., Cleveland D.W. CENP-E as an essential component of the mitotic checkpoint in vitro. Cell 2000, 102:817-826.
76. Kim Y., Holland A.J., Lan W., Cleveland D.W. Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E. Cell 2010, 142:444-455.
77. Henderson M.C., Shaw Y-JY, Wang H., Han H., Hurley L.H., Flynn G., et al. UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther 2009, 8:36-44.
78. Miyaki M., Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003, 306:799-804.
79. Shaw A.Y., Henderson M.C., Flynn G., Samulitis B., Han H., Stratton S.P., et al. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J Pharmacol Exp Ther 2009, 331:636-647.
80. Tcherniuk S., Deshayes S., Sarli V., Divita G., Abrieu A. UA62784 is a cytotoxic inhibitor of microtubules, not CENP-E. Chem Biol 2011, 18:631-641.
81. Calligaris D., Lafitte D. Chemical inhibitors: the challenge of finding the right target. Chem Biol 2011, 18:555-557.
82. Wood K.W., Lad L., Luo L., Qian X., Knight S.D., Nevins N., et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci 2010, 107:5839-5844.
83. Qian X., McDonald A., Zhou H-J., Adams N.D., Parrish C.A., Duffy K.J., et al. Discovery of the first potent and selective inhibitor of Centromere-Associated Protein E: GSK923295. ACS Med Chem Lett 2010, 1:30-34.
84. Tanudji M., Shoemaker J., L'Italien L., Russell L., Chin G., Schebye X.M. Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell 2004, 15:3771-3781.
85. Ding X., Yan F., Yao P., Yang Z., Wan W., Wang X., et al. Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin. Cell Res 2010.
86. Pinkerton AB, David RL, inventors; Kalypsys, Inc., USA, assignee. Heterocyclic derivative inhibitors of mitotic kinesin KSP, and use for the treatment of proliferative diseases. World patent WO 2007011647. 2007 Jan 25.
87. Mayr M.I., Hummer S., Bormann J., Gruner T., Adio S., Woehlke G., et al. The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. Curr Biol 2007, 17:488-498.
88. Zhu C., Zhao J., Bibikova M., Leverson J.D., Bossy-Wetzel E., Fan J.B., et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005, 16:3187-3199.
89. Gupta M.L., Carvalho P., Roof D.M., Pellman D. Plus end-specific depolymerase activity of Kip3, a kinesin-8 protein, explains its role in positioning the yeast mitotic spindle. Nat Cell Biol 2006, 8:913-923.
90. Varga V., Helenius J., Tanaka K., Hyman A.A., Tanaka T.U., Howard J. Yeast kinesin-8 depolymerizes microtubules in a length-dependent manner. Nat Cell Biol 2006, 8:957-962.
91. Catarinella M., Gruner T., Strittmatter T., Marx A., Mayer T.U. BTB-1: a small molecule inhibitor of the mitotic motor protein Kif18A. Angew Chem Int Ed Engl 2009, 48:9072-9076.
92. Boleti H., Karsenti E., Vernos I. Xklp2, a novel Xenopus centrosomal kinesin-like protein required for centrosome separation during mitosis. Cell 1996, 84:49-59.
93. Buster D.W., Baird D.H., Yu W., Solowska J.M., Chauviere M., Mazurek A., et al. Expression of the mitotic kinesin Kif15 in postmitotic neurons: implications for neuronal migration and development. J Neurocytol 2003, 32:79-96.
94. Liu M., Nadar V.C., Kozielski F., Kozlowska M., Yu W., Baas P.W. Kinesin-12, a mitotic microtubule-associated motor protein, impacts axonal growth, navigation, and branching. J Neurosci 2010, 30:14896-14906.
95. Tanenbaum M.E., Macurek L., Janssen A., Geers E.F., Alvarez-Fernandez M., Medema R.H. Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol 2009, 19:1703-1711.
96. Vanneste D., Takagi M., Imamoto N., Vernos I. The role of Hklp2 in the stabilization and maintenance of spindle bipolarity. Curr Biol 2009, 19:1712-1717.
97. Wittmann T., Boleti H., Antony C., Karsenti E., Vernos I. Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. J Cell Biol 1998, 143:673-685.
98. McDonald A, Bergnes G, Morgans DJ, inventors; Cytokinetics, Inc., USA, assignee. Preparation of quinazolinediones as Kif15 kinesin inhibitors for treating cellular proliferative disorders. US patent US 2004053948. 2004 Mar 18.
99. Manning A.L., Ganem N.J., Bakhoum S.F., Wagenbach M., Wordeman L., Compton D.A. The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. Mol Biol Cell 2007, 18:2970-2979.
100. Aoki S., Ohta K., Yamazaki T., Sugawara F., Sakaguchi K. Mammalian mitotic centromere-associated kinesin (MCAK). FEBS J 2005, 272:2132-2140.
101. Golik J., Dickey J.K., Todderud G., Lee D., Alford J., Huang S., et al. Isolation and structure determination of sulfonoquinovosyl dipalmitoyl glyceride, a P-selectin receptor inhibitor from the alga Dictyochloris fragrans. J Nat Prod 1997, 60:387-389.
102. Ohta K., Mizushina Y., Hirata N., Takemura M., Sugawara F., Matsukage A., et al. Action of a new mammalian DNA polymerase inhibitor, sulfoquinovosyldiacylglycerol. Biol Pharm Bull 1999, 22:111-116.
103. Ohta K., Mizushina Y., Hirata N., Takemura M., Sugawara F., Matsukage A., et al. Sulfoquinovosyldiacylglycerol, KM043, a new potent inhibitor of eukaryotic DNA polymerases and HIV-reverse transcriptase type 1 from a marine red alga, Gigartina tenella. Chem Pharm Bull 1998, 46:684-686.
104. Ohta K., Hanashima S., Mizushina Y., Yamazaki T., Saneyoshi M., Sugawara F., et al. Studies on a novel DNA polymerase inhibitor group, synthetic sulfoquinovosylacylglycerols: inhibitory action on cell proliferation. Mutat Res-Gen Tox En 2000, 467:139-152.
105. Coleman PJ, Garbaccio RM, Neilson LA, inventors; Merck & Co., Inc., USA, assignee. Preparation of substituted thiazoles as mitotic kinesin inhibitors. US patent US 200517677. 2005 Aug 11.
106. Karabay A., Walker R.A. Identification of microtubule binding sites in the Ncd tail domain. Biochemistry 1999, 38:1838-1849.
107. Mountain V., Simerly C., Howard L., Ando A., Schatten G., Compton D.A. The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. J Cell Biol 1999, 147:351-366.
108. Cai S., Weaver L.N., Ems-McClung S.C., Walczak C.E. Proper organization of microtubule minus ends is needed for midzone stability and cytokinesis. Curr Biol 2010, 20:880-885.
109. Lahue B.R., Ma Y., Shipps G.W., Seghezzi W., Herbst R. Substituted benzimidazoles: a novel chemotype for small molecule hKSP inhibitors. Bioorg Med Chem Lett 2009, 19:3405-3409.
110. Sheth P.R., Shipps G.W., Seghezzi W., Smith C.K., Chuang C-C., Sanden D., et al. Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain. Biochemistry 2010, 49:8350-8358.
111. Shipps GW, Ma Y, Lahue BR, Seghezzi W, Herbst R, Chaung C-C, et al, inventors; Schering Corporation, USA, assignee. Benzimidazole derivatives and related compounds for inhibiting KSP kinesin activity and their preparation and use in the treatment of KSP-associated diseases. World patent WO 2008153701. 2008 Dec 18.
112. Chan K.Y., Matthews K.R., Ersfeld K. Functional characterisation and drug target validation of a Mitotic Kinesin-13 in Trypanosoma brucei. PLoS Pathog 2010, 6:e1001050.